The FDA approves Aduhelm for the treatment of early Alzheimer's disease. Aduhelm targets brain plaque formation to slow the rate of cognitive decline.

The three botanicals are synergistically blended with a unique proprietary technology to provide fast relief of acute musculoskeletal pain.

ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

The FDA has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy in children and adults